Targeting the Microbiome to Overcome Resistance.

Simpson, Rebecca C; Shanahan, Erin; Scolyer, Richard A; Long, Georgina V

Simpson, Rebecca C; Shanahan, Erin; Scolyer, Richard A; Long, Georgina V.

Afiliación

Simpson RC; Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Charles Perkins Centre, The University of Sydney, Sydney, Australia.
Shanahan E; Charles Perkins Centre, The University of Sydney, Sydney, Australia; School of Life and Environmental Science, Faculty of Science, The University of Sydney, Australia.
Scolyer RA; Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Charles Perkins Centre, The University of Sydney, Sydney, Australia; Tissue Pathology and Diagnostic Oncology, Royal Prince A
Long GV; Melanoma Institute Australia, The University of Sydney, Sydney, Australia; Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia; Charles Perkins Centre, The University of Sydney, Sydney, Australia; Department of Medical Oncology, Royal North Shore and Ma

Cancer Cell ; 39(2): 151-153, 2021 02 08.

Article en En | MEDLINE | ID: mdl-33561397

RESUMEN

Immune checkpoint inhibition has revolutionized the treatment of many cancers, including melanoma. However, primary and acquired resistance remain key challenges for the field. Promising results from a phase I clinical trial recently published in Science highlight the potential of modulating the microbiome via fecal transplant to overcome resistance to immunotherapy.

Asunto(s)

Melanoma; Microbiota; Humanos; Inhibidores de Puntos de Control Inmunológico; Inmunoterapia; Melanoma/tratamiento farmacológico; Melanoma/genética

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Microbiota / Melanoma Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Cancer Cell Asunto de la revista: NEOPLASIAS Año: 2021 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google